Drugs / Olopatadine
Olopatadine
also known as
Olopatadine hydrochloride · Olopatadine HCL · AL-4943A · Patanase · Patanol · Allelock · ALO-4943A · KW-4679 · +11 more
Other / unclassified targets HRH1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed seasonal allergic rhinitis 1 milestone | |||||
| Filed | US (FDA) | Ryaltris | seasonal allergic rhinitis | 2018-08-10 | “Glenmark announced US FDA’s acceptance of the company’s first New Drug Application (NDA) for Ryaltris™ (olopatadine hydrochloride” glenmarkpharma.com ↗ |
| Approved Indication not stated 5 milestones | |||||
| Label expansion | US (FDA) | PATADAY ONCE DAILY RELIEF | — | 2020-07-13 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | PATADAY TWICE DAILY RELIEF | — | 2000-03-20 – 2020-02-14 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | PATANASE | — | 2009-06-17 – 2010-03-31 | fda.gov ↗ |
| Approved | EU (EMA) | Opatanol | — | 2002-05-16 | europa.eu ↗ |
| Approved | US (FDA) | PATADAY TWICE DAILY RELIEF | — | 1996-12-18 | fda.gov ↗ |
Trials 36
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01326858 | Apr → Jun 2011 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT06126952 | Oct 2023 → Feb 2024 | seasonal allergic rhinitis | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 2 | NCT03444506 | Jan → Feb 2014 | seasonal allergic rhinitis | Glenmark Pharmaceuticals Ltd. India | Completed | Met primary |
| Phase 2 | NCT01287338 | Oct 2010 → Jan 2011 | conjunctivitis | Mati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00794144 | Oct → Dec 2008 | allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 313 trials · 4 met primary | ||||||
| Phase 3 | NCT03463031 | Mar → Nov 2018 | seasonal allergic rhinitis | Glenmark Specialty S.A. | Completed | Met primary |
| Phase 3 | NCT02870205 | Aug 2016 → Jan 2017 | seasonal allergic rhinitis | Glenmark Specialty S.A. | Completed | Met primary |
| Phase 3 | NCT02709538 | Apr 2016 → Jul 2017 | perennial allergic rhinitis | Glenmark Specialty S.A. | Completed | No outcome recorded |
| Phase 3 | NCT02631551 | Mar → Jul 2016 | seasonal allergic rhinitis | Glenmark Specialty S.A. | Completed | Met primary |
| Phase 3 | NCT02322216 | Dec 2014 → Oct 2015 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT02161146 | Jun → Dec 2014 | conjunctivitis | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01743027 | Jan → Jul 2013 | eye allergy | Alcon Research | Completed | Met primary |
| Phase 3 | NCT01698814 | Oct 2012 → Jan 2013 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01037179 | Feb → May 2010 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00987272 | Oct → Nov 2009 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00578929 | Sep 2007 → Nov 2008 | seasonal allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00578331 | Dec 2006 → Jan 2008 | perennial allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00331500 | Apr → Jul 2006 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 417 trials · 1 met primary | ||||||
| Phase 4 | NCT02251613 | Dec 2013 → Jan 2014 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01697969 | Sep 2012 → Jul 2013 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01272089 | May → Dec 2011 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01282138 | Dec 2010 → Mar 2011 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01294969 | Sep 2010 → Oct 2011 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01159769 | Jun → Aug 2010 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01109485 | Mar 2010 → Jul 2011 | eye allergy | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01119287 | Mar → Sep 2010 | eye allergy | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01007253 | Nov 2009 → Apr 2010 | seasonal allergic rhinitis | University of Chicago | Completed | Met primary |
| Phase 4 | NCT00979615 | Sep → Nov 2009 | vasomotor rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00845195 | Mar → May 2009 | seasonal allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00789555 | Nov 2008 → Jan 2011 | perennial allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00772304 | Oct → Nov 2008 | allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00818805 | Jul 2008 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00691665 | May 2008 → Jan 2009 | seasonal allergic rhinitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00489398 | Jul 2007 → Dec 2008 | conjunctivitis | Hom, Milton M., OD, FAAO | Withdrawn | No outcome recorded |
| Phase 4 | NCT00389025 | Oct 2006 → Apr 2007 | eye allergy | Alcon Research | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT00609128 | Sep 2000 → Nov 2009 | conjunctivitis | University of Wisconsin, Madison | Completed | Met primary |
| Comparator or background therapy26 trials | ||||||
| Phase 1 | NCT01495338 Comparator | Dec 2011 | — | Aciex Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03320434 Comparator | Oct 2017 → Feb 2018 | conjunctivitis | ORA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02318303 Comparator | Dec 2014 → Feb 2015 | seasonal allergic rhinitis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 2 | NCT01344083 Comparator | Apr 2011 → Feb 2012 | conjunctivitis | Laboratoires Thea | Completed | No outcome recorded |
| Phase 2 | NCT00836485 Comparator | Feb → Mar 2009 | conjunctivitis | Senju USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02478398 Background | Jul 2015 → Nov 2018 | seasonal allergic rhinitis | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01657240 Comparator | Nov 2014 → Apr 2015 | conjunctivitis | Laboratorios Sophia S.A de C.V. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01700192 Background | Jan 2013 → Apr 2015 | perennial allergic rhinitis | ALK-Abelló A/S | Completed | Met primary |
| Phase 3 | NCT01479374 Comparator | Jan → Mar 2012 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01258309 Comparator | Dec 2010 → Jan 2011 | conjunctivitis, seasonal allergic rhinitis | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01435460 Comparator | Aug 2010 → Apr 2011 | conjunctivitis | Bausch & Lomb Incorporated | Completed | Met primary |
| Phase 3 | NCT00550550 Background | Nov 2007 → Sep 2009 | allergic rhinitis, conjunctivitis | ALK-Abelló A/S | Completed | Met primary |
| Phase 3 | NCT00562159 Background | Nov 2007 → Sep 2009 | allergic disease, conjunctivitis, rhinitis | ALK-Abelló A/S | Completed | Met primary |
| Phase 3 | NCT01363700 Comparator | ? → Jun 2012 | conjunctivitis | Santen Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT05314621 Comparator | Dec 2021 → Jul 2022 | conjunctivitis | Andover Research Eye Institute | Completed | No outcome recorded |
| Phase 4 | NCT05265910 Comparator | Dec 2021 → Apr 2022 | conjunctivitis | Andover Research Eye Institute | Completed | No outcome recorded |
| Phase 4 | NCT04708821 Comparator | Apr → Sep 2021 | conjunctivitis | Clinical Research Center of Florida | Completed | No outcome recorded |
| Phase 4 | NCT04776096 Comparator | Mar 2021 → Aug 2022 | eye allergy | Laboratorios Poen | Completed | No outcome recorded |
| Phase 4 | NCT03186755 Comparator | Jun 2017 → Dec 2024 | vernal conjunctivitis | Michael Marchand, MD | Unknown | No outcome recorded |
| Phase 4 | NCT01732757 Comparator | Nov → Dec 2012 | atopic conjunctivitis | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01470118 Comparator | Oct → Dec 2011 | atopic conjunctivitis | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00655109 Comparator | Feb → Mar 2008 | conjunctivitis | Greiner, Jack V., OD DO PhD | Completed | No outcome recorded |
| Phase 4 | NCT00534794 Comparator | Oct 2007 → Jan 2008 | conjunctivitis | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 4 | NCT01076439 Comparator | — | allergic rhinitis | ORA, Inc. | Withdrawn | No outcome recorded |
| — | NCT01450176 Comparator | Sep → Oct 2011 | eye allergy | McCabe Vision Center | Completed | No outcome recorded |
| — | NCT00775658 Comparator | Jan → Jun 2008 | allergic rhinitis, conjunctivitis | Vanderbilt University Medical Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 20
| Date | Issuer | Release |
|---|---|---|
| 2026-07-21 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Less Than 12 Years glenmarkpharma.com ↗
With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population. |
| 2025-11-10 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership glenmarkpharma.com ↗
Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., today announced that the National Medical Products Administration (NMPA) of China has approved RYALTRIS® Compound Nasal Spray (GSP 301 NS) for the treatment of Allergic Rhinitis (AR) in adults and children – specifically for treatment of moderate to severe seasonal AR in adults and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adult s and pediatric patients 12 years of age and older. |
| 2025-03-20 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) glenmarkpharma.com ↗
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent 1 to Pataday® 2 Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. |
| 2024-12-01 | Alembic Pharmaceuticals Ltd. | Regulatory 4th December, 2024, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) announced that it has received Tentative Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). |
| 2024-06-27 | Lupin Limited | Regulatory Lupin Receives Tentative Approval from U.S. FDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) lupin.com ↗ |
| 2023-03-01 | Alcon Research | Results Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023 alcon.com ↗
The ocular health data focuses on the benefits of Pataday’s dual-action formula and affirms the effectiveness of utilizing two mechanisms of action to provide ocular allergy itch relief: antihistamine and mast cell stabilization. |
| 2022-09-23 | Glenmark Pharmaceuticals Ltd. India | Regulatory Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada glenmarkpharma.com ↗
RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal sp ray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older. |
| 2021-09-30 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK glenmarkpharma.com ↗ |
| 2021-04-26 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age glenmarkpharma.com ↗
Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age |
| 2021-02-22 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia glenmarkpharma.com ↗
Marketing approval received from the Ministry of Health of the Russian Federation |
| 2020-07-14 | Alcon Research | Regulatory Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength alcon.com ↗ |
| 2020-02-17 | Alcon Research | Regulatory Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch alcon.com ↗
today announced that Pataday® Once Daily Relief and Pataday® Twice Daily Relief have been approved by the Food and Drug Administration (FDA) for sale over the counter (OTC) in the U.S. |
| 2019-12-20 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia glenmarkpharma.com ↗ |
| 2019-05-09 | Glenmark Pharmaceuticals Ltd. India | Results Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years glenmarkpharma.com ↗ |
| 2019-05-01 | Alembic Pharmaceuticals Ltd. | Regulatory 2nd May, 2019, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited today announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%. |
| 2018-12-01 | Alembic Pharmaceuticals Ltd. | Regulatory 101h December, 2018, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 %. |
| 2018-08-08 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals Announces FDA Acceptance of the Company’s First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis glenmarkpharma.com ↗
Glenmark Pharmaceuticals Announces FDA Acceptance of the Company’s First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis |
| 2015-02-02 | Novartis Pharmaceuticals | Regulatory Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief novartis.com ↗
Alcon, the global leader in eye care and a division of Novartis, has received approval from the US Food and Drug Administration (FDA) of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%, for the treatment of ocular itching associated with allergic conjunctivitis. |
| 2011-10-18 | Perrigo Company | Regulatory Perrigo Confirms Filing for Generic Version of PATANASE® Nasal Spray and Announcement of Patent Infringement Lawsuit by Alcon Laboratories perrigo.com ↗
The ANDA filing involved contributions from Perrigo's partner, Impax Laboratories, Inc. (Nasdaq: IPXL), who will share costs and benefits of this project. |
| 2011-07-01 | Wockhardt | Regulatory WOCKHARDT RECEIVES TENTATIVE US FDA APPROVAL FOR GENERIC VERSION OF PATANOL® OPHTHALMIC SOLUTION wockhardt.com ↗
Pharmaceutical and biotechnology major Wockhardt has received tentative approval from the United States Food & Drug Administration (US FDA) for marketing 0.1% solution of Olopatadine hydrochloride eye drops, which is used for allergic conjunctivitis. |
All press releases naming this drug 26 releases
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | olopatadine | “In this double-blind study, eligible patients (≥12 years of age) with SAR were randomized 1:1:1:1 to twice-daily GSP301 (665 μg of olopatadine and 25 μg of mometasone),...” PMID 30910440 ↗ Mar 201955“Background: Safety and efficacy of GSP301 nasal spray, an investigational fixed-dose combination of olopatadine hydrochloride and mometasone furoate, was established in three...” PMID 31248471 ↗ Jun 2019 “Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using...” PMID 26266427 ↗ Oct 2015 “Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for...” NCT00562159 ↗ “GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate.” PMID 35926824 ↗ Aug 2022 “665 μg of olopatadine twice-daily” PMID 30321655 ↗ Oct 2018 “Olopatadine HCl NS” NCT02631551 ↗ |
| Known as | AL-4943A | “The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.” NCT01037179 ↗ |
| Known as | Allelock | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | ALO-4943A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | KW-4679 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | OLO | “olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO)” NCT01007253 ↗ |
| Known as | Olopatadina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | Olopatadine (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | Olopatadine HCL | “Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily” NCT00691665 ↗4“Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril” NCT02318303 ↗ “Olopatadine HCl 1 or 2 sprays per nostril twice daily” NCT00578929 ↗ “Olopatadine HCL (Patanase) Nasal Spray, 0.6%” NCT00979615 ↗ “Olopatadine HCl ophthalmic solution, 0.1%” NCT02251613 ↗ |
| Known as | Olopatadine hydrochloride | “Are there differences in inflammatory mediators and cell surface activation markers in patients undergoing seasonal allergic conjunctivitis compared to those with sight...” NCT00609128 ↗25“A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1%...” NCT01119287 ↗ “Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication...” NCT00550550 ↗ “Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and saline nasal spray will be administered...” NCT05314621 ↗ “Background: Safety and efficacy of GSP301 nasal spray, an investigational fixed-dose combination of olopatadine hydrochloride and mometasone furoate, was established in three...” PMID 31248471 ↗ Jun 2019 “PURPOSE: To assess the efficacy and safety of a novel once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis (AC) using the...” PMID 26266427 ↗ Oct 2015 “GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate intended for seasonal allergic rhinitis...” PMID 30321655 ↗ Oct 2018 “The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.” NCT01037179 ↗ “GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate.” PMID 35926824 ↗ Aug 2022 “GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).” PMID 30910440 ↗ Mar 2019 “Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally” NCT05265910 ↗ |
| Known as | olopatadine hydrochloride (HCl) | “the antihistamine, olopatadine hydrochloride (HCl)” PMID 31053180 ↗ May 2019 |
| Known as | Olopatadine hydrochloride component of ryaltris | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | Opatanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | Pataday | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00534794 ↗ |
| Known as | Pataday once daily relief | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | Pataday Once Daily Relief Extra Strength | “Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and saline nasal spray will be administered...” NCT05314621 ↗ |
| Known as | Pataday twice daily relief | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Known as | Patanase | “Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%)” NCT00794144 ↗2“Olopatadine HCL (Patanase) Nasal Spray, 0.6%” NCT00979615 ↗ “Olopatadine Nasal Spray (Patanase)” NCT01076439 ↗ |
| Known as | Patanol | “Are there differences in inflammatory mediators and cell surface activation markers in patients undergoing seasonal allergic conjunctivitis compared to those with sight...” NCT00609128 ↗2“A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1%...” NCT01119287 ↗ |
| Known as | Pazeo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189432 ↗ |
| Action | Inhibit | “a mast cell stabilizer that inhibits the release of histamine and other proinflammatory mediators from human conjunctival mast cells” NCT03186755 ↗1“Histamine H1 receptor antagonist” CHEMBL1189432 ↗ |
| Modality | Other / unclassified | “an antihistamine drop in the eye” NCT01007253 ↗ |
| Route | Other | “dosed intraocularly” NCT00550550 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL1189432 ↗ |